Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Presentations at the 81st scientific sessions of the American Diabetes Association, part 2.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Bloomgarden ZT;Bloomgarden ZT
  • Source:
    Journal of diabetes [J Diabetes] 2021 Nov; Vol. 13 (11), pp. 844-846. Date of Electronic Publication: 2021 Aug 24.
  • Publication Type:
    Editorial
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101504326 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1753-0407 (Electronic) Linking ISSN: 17530407 NLM ISO Abbreviation: J Diabetes Subsets: MEDLINE
    • Publication Information:
      Original Publication: Richmond, Vic. : Blackwell Publishing Asia, 2009-
    • Subject Terms:
      Glucagon-Like Peptide-1 Receptor Agonists*; Diabetes Mellitus/*drug therapy ; Hypoglycemic Agents/*therapeutic use ; Renal Insufficiency, Chronic/*prevention & control ; Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use; Diabetes Mellitus/pathology ; Humans ; Renal Insufficiency, Chronic/pathology
    • References:
      Lee MK, Kim B, Han K, et al. Sodium-glucose cotransporter 2 inhibitors and risk of retinal vein occlusion among patients with type 2 diabetes: a propensity score-matched cohort study. Diabetes Care. 2021;dc203133. https://doi.org/10.2337/dc20-3133.
      Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9:563-574. https://doi.org/10.1016/S2213-8587(21)00174-1.
      Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2108269.
      Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515. https://doi.org/10.1056/NEJMoa2107519.
    • Accession Number:
      0 (Hypoglycemic Agents)
      0 (Sodium-Glucose Transporter 2 Inhibitors)
      0 (Glucagon-Like Peptide-1 Receptor Agonists)
    • Publication Date:
      Date Created: 20210816 Date Completed: 20220228 Latest Revision: 20250103
    • Publication Date:
      20250114
    • Accession Number:
      10.1111/1753-0407.13219
    • Accession Number:
      34396702